Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Extension of Convertible Loan Notes

23rd May 2025 07:00

RNS Number : 8808J

Roquefort Therapeutics PLC

23 May 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Extension of Convertible Loan Notes

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, announces that it has agreed with the holders of its convertible loan notes ("CLNs") to extend the maturity date to 31 December 2025.

On 23 May 2024 the Board resolved to issue CLNs with a total face value of £655,000. After taking into account previous conversions, there are currently CLNs with a total face value of £307,894 outstanding ("Remaining CLNs"). The Remaining CLNs were due to mature today ("Maturity Date"); however, the Company has agreed with the holders of the Remaining CLNs to extend the Maturity Date to 31 December 2025. All other terms and conditions of the CLNs remain unchanged.

Stephen West, Roquefort Therapeutics Chairman commented:

"We are pleased that the holders of the Remaining CLNs have agreed to extend the maturity date to the end of the year. This allows us sufficient time to focus on completing the previously announced Lyramid and Oncogeni transactions, whilst assessing other clinical stage assets and/or revenue generating life science businesses for possible M&A activity."

Regulatory Information

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

ENDS

Enquiries:

Roquefort Therapeutics plc	+44 (0)20 3918 8633
Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
SP Angel Corporate Finance LLP (Broker) David Hignell / Vadim Alexandre / Devik Mehta	+44 (0) 20 3470 0470
Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper	+44 (0)20 7466 5000
Peak IR (Investor Relations) Seb Wykeham	+33 (0)7 44 44 15 42

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the immunology and oncology markets prior to securing a value accretive exit.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLLLLEELBBBV

Related Shares:

FTSE 100 Latest

Value8,772.38

Change55.93